WO2005117584A3 - Distribution transmucosale de peptides et de proteines amelioree - Google Patents
Distribution transmucosale de peptides et de proteines amelioree Download PDFInfo
- Publication number
- WO2005117584A3 WO2005117584A3 PCT/US2005/001440 US2005001440W WO2005117584A3 WO 2005117584 A3 WO2005117584 A3 WO 2005117584A3 US 2005001440 W US2005001440 W US 2005001440W WO 2005117584 A3 WO2005117584 A3 WO 2005117584A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proteins
- enhancing
- peptides
- compositions
- absorption
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 238000010521 absorption reaction Methods 0.000 abstract 5
- 230000002708 enhancing effect Effects 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- 230000000975 bioactive effect Effects 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010011459 Exenatide Proteins 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- -1 PYY3-36 Chemical compound 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des méthodes et des compositions permettant d'améliorer l'absorption transmucosale de protéines et peptides bioactifs. L'invention concerne plus particulièrement des compositions permettant d'améliorer l'absorption transmucosale de protéines et peptides bioactifs, tels que l'exendine-4, PYY, PYY3-36, et GLP-1 et leurs analogues et dérivés. Lesdites compositions comprennent un mélange d'acide polyamino cationique permettant d'améliorer l'absorption, au moins un agent d'amélioration d'absorption supplémentaire et un tampon compatible avec l'acide polyamino. L'invention concerne également des méthodes permettant d'améliorer l'absorption transmucosale et la biodisponibilité des protéines et des peptides bioactifs à l'aide de ces compositions.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/628,123 US20090069226A1 (en) | 2004-05-28 | 2005-01-12 | Transmucosal delivery of peptides and proteins |
| US14/570,295 US20150157725A1 (en) | 2004-05-28 | 2014-12-15 | Transmucosal delivery of peptides and proteins |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2004/017456 WO2005000222A2 (fr) | 2003-05-30 | 2004-05-28 | Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines |
| USPCT/US2004/017456 | 2004-05-28 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/628,123 A-371-Of-International US20090069226A1 (en) | 2004-05-28 | 2005-01-12 | Transmucosal delivery of peptides and proteins |
| US14/570,295 Continuation US20150157725A1 (en) | 2004-05-28 | 2014-12-15 | Transmucosal delivery of peptides and proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005117584A2 WO2005117584A2 (fr) | 2005-12-15 |
| WO2005117584A3 true WO2005117584A3 (fr) | 2006-03-16 |
Family
ID=35463275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/001440 WO2005117584A2 (fr) | 2004-05-28 | 2005-01-12 | Distribution transmucosale de peptides et de proteines amelioree |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2005117584A2 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442682B2 (en) * | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| HUE038748T2 (hu) | 2012-12-21 | 2018-11-28 | Sanofi Sa | Exendin-4 származékok, mint duális GLP1/GIP- vagy trigonális GLP1/GIP/glukagon-agonisták |
| EP3080150B1 (fr) | 2013-12-13 | 2018-08-01 | Sanofi | Analogues peptidiques d'exendine-4 en tant qu'agonistes du récepteur gip/glp-1 double |
| WO2015086733A1 (fr) | 2013-12-13 | 2015-06-18 | Sanofi | Agonistes mixtes des récepteurs du glp-1/glucagon |
| WO2015086729A1 (fr) | 2013-12-13 | 2015-06-18 | Sanofi | Agonistes mixtes des récepteurs glp-1/gip |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4847240A (en) * | 1978-01-16 | 1989-07-11 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
| WO2000041546A2 (fr) * | 1999-01-14 | 2000-07-20 | Amylin Pharmaceuticals, Inc. | Nouvelles formulations d'agonistes de l'exendine et modes d'administration |
-
2005
- 2005-01-12 WO PCT/US2005/001440 patent/WO2005117584A2/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4847240A (en) * | 1978-01-16 | 1989-07-11 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
| WO2000041546A2 (fr) * | 1999-01-14 | 2000-07-20 | Amylin Pharmaceuticals, Inc. | Nouvelles formulations d'agonistes de l'exendine et modes d'administration |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005117584A2 (fr) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005000222A3 (fr) | Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines | |
| WO2005117584A3 (fr) | Distribution transmucosale de peptides et de proteines amelioree | |
| WO2006024275A3 (fr) | Invention concernant le glp-1 et l'exendine | |
| WO2007047834A3 (fr) | Conjugués de peptides pour administration par voie orale pour traiter des maladies métaboliques | |
| WO2007022255A3 (fr) | Preparations pharmaceutiques a liberation prolongee | |
| WO2010030670A3 (fr) | Compositions et procédés permettant d’éviter la dégradation oxydative des protéines | |
| ZA200706917B (en) | Aprotinin polypeptides for transporting a compound across the blood-brain barrier | |
| HK1088840A1 (en) | Stable analogs of glp-1 glp-1 | |
| WO2002074247A3 (fr) | Formulations pharmaceutiques a liberation prolongee | |
| WO2006017251A3 (fr) | Compositions pour l'apport du peptide yy et d'agonistes du pyy | |
| WO2003064619A3 (fr) | Compositions a action prolongee d'hormones et de facteurs de croissance et leurs utilisations | |
| WO2005115406A3 (fr) | 8-(2-hydroxyphenoxy)octyldiethanolamine et ses sels utile dans l'administration d'agents actifs | |
| WO2009086400A3 (fr) | Formulation de vwf recombinant | |
| EA200701065A1 (ru) | Инъецируемые составы, содержащие нанодисперсный оланзапин | |
| PT2415484E (pt) | Composição anestésica local prolongada contendo aibs | |
| TW200745334A (en) | Compositions and methods for producing a composition | |
| WO2004104018A3 (fr) | Compostions d'administration de peptide yy de d'agonistes pyy | |
| WO2009146024A8 (fr) | Analogues d’étomidate ayant des propriétés pharmacocinétiques et pharmacodynamiques améliorées | |
| IL177529A0 (en) | Stable injectable diclofenac compositions | |
| WO2008033395A3 (fr) | Protéines de fusion mélanocortine et transferrine | |
| WO2005067893A3 (fr) | Compositions pharmaceutiques contenant du midazolam dans une concentration elevee | |
| WO2004005262A8 (fr) | Nouveaux antagonistes des recepteurs du neuropeptide y y5 | |
| EP1604662A8 (fr) | Derivés de la benzyl amine du acide carboxylique (2R) de la 1-¬(3R)-Amino-4-(2-fluoro-phenyl)-butyl|-pyrrolidine et composés similaires pour l'utilisation comme inhibiteurs de la peptidase dipeptidyl IV (DPP-IV) pour le traitement de la diabetes mellitus de type 2 | |
| WO2009064366A3 (fr) | Procédés et compositions pour un marquage protéique à l'aide d'acide lipoïque ligases | |
| EA200800181A1 (ru) | Фармацевтическая композиция glp-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 11628123 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |